Trial · NCT04666636
Mechanisms for Activation of Beige Adipose Tissue in Humans
NCT04666636, Phase 2, Recruiting, Philip Kern
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mechanisms for Activation of Beige Adipose Tissue in Humans. Trials, record NCT04666636. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04666636
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mechanisms for Activation of Beige Adipose Tissue in Humans
- NCT number
- NCT04666636
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 65 participants, estimated
- Lead sponsor
- Philip Kern
- Conditions
- PreDiabetes
- Interventions
- Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
- First posted
- 2020-12-14
- Last updated
- 2026-07-07
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Glucose Tolerance | 16 weeks (at baseline and at 16 weeks) | The standard oral glucose tolerance test (OGTT) using 75g glucose will be used to assess tolerance. |
| Primary | Change in Body Composition | 16 weeks (at baseline and at 16 weeks) | Body composition (percent body fat) will be measured using dual-energy X-ray absorptiometry (DEXA). |
| Primary | Change in Resting Metabolic Rate | 16 weeks (at baseline and at 16 weeks) | Resting Metabolic Rate (RMR) will be measured using indirect calorimetry. |
| Primary | Change in Brown Adipose Tissue Activity | 16 weeks (at baseline and at 16 weeks) | Brown adipose tissue (BAT) activity will be measured using water-vest cold stimulation combined with positron emission tomography (PET-CT). |
| Primary | Change in Peripheral Insulin Sensitivity | 16 weeks (at baseline and at 16 weeks) | Peripheral insulin sensitivity will be measured with a euglycemic clamp. |
| Primary | Change in Insulin Secretion | 16 weeks (at baseline and at 16 weeks) | Insulin secretion will be measured with a euglycemic clamp. |
| Primary | Change in glycohemoglobin | 16 weeks (at baseline and at 16 weeks) | Hemoglobin A1c (HbA1C) will be measured from blood samples. |
| Primary | Change in Matsuda Index for Dosing Sub Study | Baseline, week 6, week 12, week 18 | Comparison of change in Matsuda Index as determined by 2-h oral glucose tolerance test (OGTT). During OGTT, response to oral 75g glucose intake is determined by measuring insulin and glucose in timed samples obtained at 0, 30, 60, 90 and 120 min. Increase in scores reflect improvement in whole body insulin sensitivity. |
| Primary | Change in bile acids/blood proteins | Baseline, week 1, week 2 | FGF-19 and total bile acids will be analyzed and compared across the different conditions. Plasma bile acid concentration (ng/mL) will be measured and compared across the different doses of study drug. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK124626 | Mechanisms for activation of beige adipose tissue in humans | KERN, PHILIP A | UNIVERSITY OF KENTUCKY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04666636
GET https://conductscience.org/api/trials/v1/NCT04666636/registered